Scarica l'app Stockscreener
8.95
2.05%
0.18
Dopo l'orario di chiusura:
8.95
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
KYTX: Pivotal miv-cel data in SPS shows disease reversal, with BLA filing and launch planned this year - TradingView
How Kyverna Therapeutics Inc. stock compares to growth peersWeekly Stock Report & Long Hold Capital Preservation Tips - Naître et grandir
Portfolio Recap: Is Kyverna Therapeutics Inc stock trending bullishBreakout Watch & Safe Entry Zone Tips - baoquankhu1.vn
Kyverna to present stiff person syndrome trial data at AAN meeting - Investing.com Australia
Kyverna secures up to $150M loan facility from Oxford Finance - MSN
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - Sahm
Kyverna Therapeutics Announces Presentations on Miv-cel Research at AAN Annual Meeting 2026 - Quiver Quantitative
New cell therapy data in stiff person syndrome set for AAN 2026 - Stock Titan
Aug Fed Impact: What is the Moat Score of Kyverna Therapeutics IncWeekly Profit Recap & Verified Short-Term Trading Plans - baoquankhu1.vn
Director Andrew Craig Miller files initial Form 3 at Kyverna (KYTX) - Stock Titan
Kyverna Therapeutics (KYTX) director awarded options and RSUs in equity grant - Stock Titan
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - Bitget
Biotech Kyverna lines up March talks at Leerink, Jefferies events - Stock Titan
Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution - Seeking Alpha
P5002025 Year in Review & Long-Term Safe Return Strategies - mfd.ru
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Director at Kyverna Therapeutics (KYTX) granted options and RSUs - Stock Titan
Kyverna Therapeutics (KYTX) director Emany Sravan Kumar files Form 3 - Stock Titan
Is Kyverna Therapeutics Inc. undervalued by DCF analysisMarket Volume Report & AI Powered Trade Plan Recommendations - mfd.ru
Intellia’s New Cell Therapy Alliances Add Optionality To Growth Story - Sahm
Kyverna adds two directors as board prepares for commercial stage By Investing.com - Investing.com Canada
Beam Therapeutics Inc. announced that it expects to receive $500 million in funding - marketscreener.com
Kyverna Therapeutics Strengthens Board With New Director Appointments - TipRanks
Kyverna Therapeutics appoints biotech leaders Sravan Emany and Andrew Miller to board of directors - marketscreener.com
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors - Bitget
Biotech leaders join Kyverna Therapeutics (KYTX) board as Spiegelman exits - Stock Titan
KYTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
KYTXKyverna Therapeutics Latest Stock News & Market Updates - Stock Titan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Bain Capital Life Sciences discloses 5.4% Kyverna (KYTX) ownership stake - Stock Titan
Rubin-led Northpond funds show 6.1% Kyverna (KYTX) stake in 13G/A - Stock Titan
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year - Yahoo Finance
What’s Kyverna Therapeutics Inc.’s historical returnOil Prices & Safe Investment Capital Preservation Plans - mfd.ru
Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat
What is the Moat Score of Kyverna Therapeutics IncMarket Risk Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
Does Kyverna Therapeutics Inc. outperform in volatile marketsJuly 2025 EndofMonth & Verified Entry Point Signals - mfd.ru
Profit Review: Can Kyverna Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Value Report & Reliable Volume Spike Trade Alerts - mfd.ru
Kyverna Therapeutics (KYTX) CTO Mayobanex Pujols reports no share ownership on Form 3 - Stock Titan
Stock Recap: Is AIRT a defensive stockWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
Myasthenia Gravis Market Forecast Indicates 10.4% CAGR Growth by 2034, Reports DelveInsight - Barchart.com
Aug Reactions: Can Kyverna Therapeutics Inc weather a recessionQuarterly Market Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Aug PostEarnings: Does Koninklijke Philips NV Depositary Receipt outperform in volatile marketsQuarterly Trade Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Income Plays: Can Kyverna Therapeutics Inc maintain sales growthJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Aug Momentum: How Kyverna Therapeutics Inc. stock performs after earningsEarnings Miss & Short-Term Trading Opportunity Alerts - mfd.ru
Kyverna Therapeutics appoints Mayo Pujols as chief technology officer By Investing.com - Investing.com Nigeria
Kyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing - TipRanks
Kyverna Therapeutics appoints Mayo Pujols as chief technology officer - Investing.com
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer - Quiver Quantitative
Fund Flows: Is Kyverna Therapeutics Inc stock trending bullishEarnings Trend Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Valuation Update: Is Scully Royalty Ltd on track to beat earningsGold Moves & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Street Watch: Can Kyverna Therapeutics Inc weather a recessionSell Signal & Safe Entry Zone Identification - baoquankhu1.vn
Macro Review: Can Kyverna Therapeutics Inc weather a recession2025 Earnings Surprises & High Return Trade Guides - baoquankhu1.vn
KYTX stock just surged 11% today – what is the connection with stiff person syndrome? - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Does Kyverna Therapeutics Inc outperform in volatile markets2025 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Volume Summary: Will Launch One Acquisition Corp benefit from AI trendsJuly 2025 Closing Moves & Weekly Sector Rotation Insights - baoquankhu1.vn
Risk Report: Will Kyverna Therapeutics Inc outperform tech stocksTrade Analysis Summary & Community Verified Trade Signals - baoquankhu1.vn
What momentum indicators show for Kyverna Therapeutics Inc. stockPrice Action Analysis & Follow Top Performers in the Community - bollywoodhelpline.com
Will Kyverna Therapeutics Inc. stock see PE expansionWeekly Investment Report & Capital Efficiency Focused Strategies - bollywoodhelpline.com
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):